The present study evaluated the real-world efficacy and safety of the zanubrutinib combined with R-CHOP (ZR-CHOP) regimen in patients with MYD88-mutated DLBCL-nos. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.